ADAR1 Capital Management, LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001940272

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q2 2026 · 268 positions · Total reported value $1.81B · Top-10 concentration 34.2% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 47.5% · 33 new · 62 cut · 48 exited

Active Share (vs S&P 500): 98.9% · vs QQQ: 99.4% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -7.0% · vs SPY -9.1% · Prev Value $1.81B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -3.7% · vs SPY -5.9% · Latest Value $1.82B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q2 2026 13F filing, ADAR1 Capital Management, LLC disclosed 268 equity positions with a combined reported value of $1.81B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 34.2% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were PTGX ($117.78M), ROIV ($111.73M), IMVT ($89.80M). By sector, the heaviest allocations are Health Care 86.5%, Financials 2.6%. Versus the prior quarter, allocation shifted toward Health Care (+2.8pp), Financials (+0.6pp) and away from Other (-3.1pp).

Versus the prior quarter, ADAR1 Capital Management, LLC opened 33 new positions, trimmed 62 and fully exited 48, a turnover rate of 47.5% of positions. The portfolio's overlap with the prior quarter was 67% of names.

The largest new positions opened in Q2 2026 were EDIT ($28.80M), VOR ($12.53M), FTH ($9.03M).

Of the 48 positions fully exited versus the prior quarter, the largest were BEAM ($34.47M), SRRK ($20.02M), TERN ($10.54M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • EDIT EDITAS MEDICINE INC · $28.80M
  • VOR VOR BIOPHARMA INC · $12.53M
  • FTH FAETH THERAPEUTICS INC · $9.03M
  • AMAN AMANAT ACQUISITION CORP · $7.62M
  • RACC RESEARCH ALLIANCE CORP III · $6.96M
  • RLAY RELAY THERAPEUTICS INC · $6.70M
  • DGACU DISCIPLINED GROWTH ACQUIS CO · $5.02M
  • BOLD BOUNDLESS BIO INC · $4.92M

Fully Exited (vs previous quarter)

  • BEAM BEAM THERAPEUTICS INC · prev qtr: $34.47M · history
  • SRRK SCHOLAR ROCK HLDG CORP · prev qtr: $20.02M
  • TERN TERNS PHARMACEUTICALS INC · prev qtr: $10.54M
  • VRTX VERTEX PHARMACEUTICALS INC · prev qtr: $6.73M
  • VRDN VIRIDIAN THERAPEUTICS INC · prev qtr: $5.95M
  • LLY ELI LILLY & CO · prev qtr: $4.65M
  • DNTH DIANTHUS THERAPEUTICS INC · prev qtr: $4.62M
  • BLTE BELITE BIO INC · prev qtr: $4.29M

Insider Transactions (Form 4)

Latest ADAR1 Capital Management, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-11-11 Buy NextCure, Inc. 12,333 $5.10 SEC filing
2026-11-06 Buy NextCure, Inc. 3,662 $5.10 SEC filing
2026-11-05 Buy InMed Pharmaceuticals Inc. 2,640 $13.10 SEC filing
2026-11-05 Buy NextCure, Inc. 1,024 $5.10 SEC filing
2026-10-27 Buy NextCure, Inc. 3,553 $5.10 SEC filing
2026-10-26 Buy NextCure, Inc. 1,672 $5.03 SEC filing
2026-10-23 Buy InMed Pharmaceuticals Inc. 4 $1.32 SEC filing
2026-10-23 Buy NextCure, Inc. 5,626 $4.83 SEC filing

All insider transactions →

Fund Profile

ADAR1 Capital Management, LLC is an SEC-registered 13F filer based in Austin, TX, United States. As of Q2 2026 it reported 268 US equity positions with a combined value of $1.81B. HoldingsHub carries 11 quarters of its filings (Q4 2023–Q2 2026).

Firm Snapshot

  • Headquarters: AUSTIN, TX, United States
  • SEC registration: 801-130082 (status: Approved), registered 2024-04-25
  • Regulatory AUM (Form ADV): $1.68B as of 2026-03-31
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 2 private funds, of which 2 hedge funds

Portfolio Structure

  • 268 positions · $1.81B reported value (Q2 2026)
  • Top 10 holdings = 34.2% of reported value
  • Largest position: PTGX (PROTAGONIST THERAPEUTICS INC) at 6.5%
  • Average position size: $6.74M

Sector Tilt

  • Health Care 86.5%
  • Financials 2.6%
  • Industrials 0.4%
  • (classified holdings cover 90% of value)

Quarterly Activity

  • Q2 2026: 42 new, 99 added, 60 reduced, 69 exited
  • 67 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 86.5%
Financials 2.6%
Other 10.4%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 960.86K $117.78M 6.52%
6.52%
Reduce
2 3.16M $111.73M 6.19%
6.19%
Reduce
3 2.33M $89.80M 4.97%
4.97%
Reduce
4 3.37M $64.01M 3.55%
3.55%
Add
5 1.29M $47.80M 2.65%
2.65%
Add
6 1.22M $45.73M 2.53%
2.53%
Add
7 337.12K $39.47M 2.19%
2.19%
Hold
8 457.91K $39.01M 2.16%
2.16%
Reduce
9 940.75K $31.51M 1.75%
1.75%
Reduce
10 3.15M $30.98M 1.72%
1.72%
Reduce
11 8.89M $28.80M 1.59%
1.59%
New
12 1.03M $26.47M 1.47%
1.47%
Reduce
13 283.98K $25.21M 1.40%
1.40%
Reduce
14 2.46M $25.03M 1.39%
1.39%
Reduce
15 74.25K $24.86M 1.38%
1.38%
Add
16 228.52K $24.36M 1.35%
1.35%
Add
17 619.54K $23.05M 1.28%
1.28%
Add
18 574.04K $22.39M 1.24%
1.24%
Add
19 3.04M $20.71M 1.15%
1.15%
Add
20 217.59K $20.15M 1.12%
1.12%
Reduce
21 7.42M $19.95M 1.10%
1.10%
Add
22 387.72K $19.68M 1.09%
1.09%
Add
23 1.34M $19.60M 1.09%
1.09%
Add
24 62.50K $18.78M 1.04%
1.04%
Add
25 25.00K $18.67M 1.03%
1.03%
Reduce
26 244.18K $17.05M 0.94%
0.94%
Add
27 374.62K $16.71M 0.93%
0.93%
Reduce
28 87.51K $16.39M 0.91%
0.91%
Reduce
29 185.62K $15.93M 0.88%
0.88%
Reduce
30 1.55M $15.22M 0.84%
0.84%
Reduce
31 136.16K $15.12M 0.84%
0.84%
Reduce
32 7.39M $15.00M 0.83%
0.83%
Add
33 324.67K $14.95M 0.83%
0.83%
Add
34 926.35K $14.82M 0.82%
0.82%
Add
35 22.21K $13.85M 0.77%
0.77%
Add
36 3.61M $13.63M 0.76%
0.76%
Add
37 404.01K $13.41M 0.74%
0.74%
Reduce
38 166.29K $13.18M 0.73%
0.73%
Add
39 730.65K $13.13M 0.73%
0.73%
Add
40 3.37M $12.62M 0.70%
0.70%
Reduce
41 680.63K $12.53M 0.69%
0.69%
New
42 135.59K $12.43M 0.69%
0.69%
Hold
43 3.76M $12.03M 0.67%
0.67%
Add
44 1.02M $11.70M 0.65%
0.65%
Add
45 822.65K $10.73M 0.59%
0.59%
Add
46 67.40K $10.67M 0.59%
0.59%
Add
47 1.00M $10.60M 0.59%
0.59%
Hold
48 1.76M $10.38M 0.57%
0.57%
Add
49 2.24M $10.21M 0.56%
0.56%
Reduce
50 339.28K $10.12M 0.56%
0.56%
Add

FAQ

What did ADAR1 Capital Management, LLC buy in 2026-Q2?

In its 2026-Q2 13F filing, ADAR1 Capital Management, LLC reported 268 equity positions worth $1.81B in aggregate; its largest disclosed positions were PTGX ($117.78M), ROIV ($111.73M), IMVT ($89.80M).

How large is ADAR1 Capital Management, LLC's portfolio?

ADAR1 Capital Management, LLC reported $1.81B of long equity holdings across 268 positions as of 2026-Q2. Top-10 holdings account for 34.2% of reported value.

What is ADAR1 Capital Management, LLC's investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/adar1-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →